BLOG
Join the Conversation
Market “Highs”: Canopy Growth consolidating within a classic symmetrical triangle pattern
The technical consolidation reflects the company’s fundamental risk-reward picture -- attractive growth balanced by increasing expenses growth and dilution. Revenue, although inorganic, has grown 2X-3X form a low base over the last calendar year; and the large...
Spread Trading Newsletter April 23 2018: Soybean Oil
Authored by Vittoria Onufrio via Halifax America Let's take a look at the following spread BON18-BOZ18 (Soybean oil) The Spread Indicator entered the overbought level. The indicator crossed above 80 suggesting that the July 2018 Soybean oil contract is weaker than the...
Spread Trading Newsletter April 23 2018: Soybean
Authored by Vittoria Onufrio via Halifax America Let's take a look at the following spread SN18-SQ18 (Soybean) The Spread Indicator entered the oversold level. The indicator crossed below - 80 suggesting that the July 2018 soybean contract is stronger than the August...
Market “Highs”: Emerald Health Therapeutics – Two Technical Views
Emerald Therapeutics (EMHTF), the 10 largest cannabis stocks by market cap, is a major Canadian cannabis grower. From December 2017 to February 2018, trading volume jumped as was the case with all cannabis stocks. Technically, this increase in trading volume and...
34 Reasons Supporting the Cannabis Industry’s Potential for Global Growth
Right now, investors are focusing on Canada’s anticipated cannabis legalization for recreational use this summer. This event alone can have a significantly positive impact on the industry. Yet this event merely marks the beginning for this emerging industry. Let’s...
Emerald Health Therapeutics Inc (EMHTF) Continues Its Downward Slide
In stark contrast to GW Pharmaceuticals (GWPH), Emerald Health continues its slide. Here’s a quick technical breakdown. One technical view would be to see the current price levels around the neck level of a Head & Shoulders pattern. If we can assume that’s...
THE FED IS NOW USING TRUMP’S ACTIONS TO MASK THE ECONOMY’S COLLAPSE
Editorial note: this is a re-post from GSI Exchange. Here's the issue: alarming information can be expressed in an alarmist or non-alarminst way. Thie following article uses alarmist rhetoric. This shouldn't, however, take away from the main points, some of which are...
WHAT HAPPENS WHEN THE STATE AND DEEP STATE GET THEIR HANDS ON ARTIFICIAL INTELLIGENCE
Source: GSI Exchange At the time of writing, Mark Zuckerberg is appearing before the Senate to answer questions regarding the Facebook’s data breach. You can imagine how many citizens and politicians are probably clamoring for tighter regulations over the...
3 Critical Factors to Affect the Marijuana Industry in 2018
Here’s the skinny (skimmed from The Motley Fool): One: The highly anticipated legalization of recreational marijuana use in Canada this summer. Two: The FDA approves GW Pharmaceutical’s Epidiolex, a cannabis-based drug for childhood epilepsy. Three: Gallup poll...
Market Highs: GW Pharmaceuticals Breaks Out Pending FDA Review
Chart: Tradingview Last Tuesday, April 17, GW Pharmaceuticals (GWPH), known for its development of cannabis-derived medications, broke out of its downtrend in anticipation that its latest drug, Epidiolex—a treatment for childhood epilepsy—may favorably be reviewed and...
The risk of loss in trading stocks, options, foreign equities, and bonds can be substantial and is not suitable for all investors. Trading on margin is not suitable for all investors and losses exceeding your initial deposit is possible. Supporting documentation is available upon request. Day trading is high risk, speculative trading strategy and not suitable for all investors. Carefully consider whether trading is suitable for you in light of your circumstances, knowledge, and financial resources and only risk capital should be used. You are fully responsible for any investment decision you make. Halifax America does not make investment recommendations and does not provide tax, financial, or legal advice.
Partners and regulatory bodies
